

---

<b>INDEX .....</b>	<b>1</b>
<b>ABBREVIATIONS.....</b>	<b>5</b>
<b>ABSTRACT .....</b>	<b>13</b>
<b>RESUMEN .....</b>	<b>19</b>
<b>RESUM .....</b>	<b>25</b>
<b>I. INTRODUCTION .....</b>	<b>31</b>
1. CYCLOOXYGENASE AND PROSTAGLANDINS .....	33
1.1 Cyclooxygenase description, function, and localisation.....	33
1.1 COX isoforms, expression, and regulation .....	34
1.2 Prostanoids and prostaglandins.....	36
2. PROSTAGLANDINS AND COX-2 IN HEPATIC PHYSIOPATHOLOGY .....	38
2.1 The liver: function and structure.....	38
2.2 Hepatic COX-2 expression.....	40
2.3 COX-2 in liver pathology.....	41
3. LIVER ISCHEMIA-REPERFUSION INJURY .....	43
3.1 Liver transplant.....	43
3.2 Ischemia-reperfusion injury.....	44
3.3 Inflammatory immune response.....	46
3.3.1 <i>Liver macrophages activation and recruitment.....</i>	<i>47</i>
3.3.2 <i>Neutrophil activation and recruitment .....</i>	<i>48</i>
3.4 Oxidative stress and antioxidant response .....	48
3.5 Endoplasmic reticulum stress .....	49
3.6 Cellular death.....	51
3.6.1 <i>Apoptosis.....</i>	<i>51</i>
3.6.2 <i>Necrosis .....</i>	<i>52</i>
3.7 Autophagy.....	53
4. MITOCHONDRIA.....	54
4.1 Mitochondrial respiration .....	56
4.1.1 <i>Electron transport chain and oxidative phosphorylation system.....</i>	<i>56</i>
4.1.1 <i>Supercomplexes .....</i>	<i>57</i>
4.2 Mitochondrial dynamics.....	60
4.3 Role of the mitochondria in ischemia-reperfusion injury .....	62
<b>II. OBJECTIVES .....</b>	<b>65</b>
<b>III. MATERIALS AND METHODS.....</b>	<b>69</b>
1. REAGENTS AND EQUIPMENT.....	71
2. ANIMAL MODELS AND EXPERIMENTAL DESIGN.....	72
2.1 Generation and maintenance of the <i>h-COX-2 Tg</i> mice.....	72

2.2	Pure genetic background <i>h-COX-2</i> Tg mice line generation (B6).....	74
2.3	F1 hybrid genetic background animals (B6D2 F1) .....	74
2.4	Mice genotyping .....	74
2.5	Experimental design.....	76
2.5.1	<i>Liver ischemia-reperfusion model</i> .....	76
2.5.2	<i>Ischemia preconditioning</i> .....	77
2.5.3	<i>Drug-inhibition of COX-2</i> .....	78
3.	SUBCELLULAR FRACTIONATION .....	78
3.1	Mitochondrial isolation .....	78
3.2	Nuclear fractionation.....	79
4.	HISTOLOGICAL ANALYSIS.....	80
4.1	Fixation, paraffin tissue inclusion, and sectioning.....	80
4.2	Deparaffination, rehydration, and dehydration of samples .....	80
4.3	Fixed paraffined tissue stains.....	80
4.3.1	<i>H&amp;E staining</i> .....	80
4.3.2	<i>Ly6G<sup>+</sup> staining</i> .....	81
4.4	Tissue cryopreservation and sectioning.....	82
4.5	Dihydroethidium staining.....	82
4.6	Transmission Electronic Microscopy (TEM) .....	82
5.	PROTEIN DETECTION .....	83
5.1	Protein extraction and quantification .....	83
5.2	Protein electrophoresis and immunoblotting .....	84
5.3	Protein native electrophoresis for supercomplex detection (BN-PAGE).....	85
5.4	Immunofluorescence .....	88
6.	GENE DETECTION AND EXPRESSION.....	88
6.1	Isolation of total DNA from frozen liver tissue .....	88
6.2	Determination of mitochondrial DNA content .....	89
6.3	RNA extraction, RT, and qPCR.....	90
6.4	Determination of <i>Xbp1</i> splicing.....	93
6.5	RNAseq and NGS analysis.....	94
7.	DETERMINATION OF METABOLITES AND CYTOKINES .....	94
7.1	Plasma collection .....	94
7.2	PGE <sub>2</sub> .....	94
7.3	Plasma transaminases.....	95
7.4	Plasma cytokines.....	95
7.5	Total NAD and NADH content determination .....	96
7.6	AMP and ATP determination .....	96
8.	ENZYMATIC ACTIVITIES .....	97
8.1	Caspase 3.....	97
8.2	Catalase .....	97
8.3	Superoxide dismutase.....	97
8.4	Glutathione reductase and Glutathione Peroxidase .....	98
8.5	Total glutathione and oxidised glutathione measurement.....	98
8.6	Myeloperoxidase activity .....	99
8.7	Indirect measurement of ROS production .....	99
9.	FUNCTIONAL ASSAYS.....	100
9.1	Measurement of mitochondrial membrane potential .....	100

---

9.2	High resolution respirometry .....	100
10.	PATIENTS .....	103
11.	STATISTICS .....	103
<b>IV.</b>	<b>RESULTS .....</b>	<b>105</b>
1.	CHARACTERIZATION OF THE ROLE OF COX-2 IN HEPATIC ISCHEMIA-REPERFUSION MODEL .....	109
1.1	Establishment of the ischemia-reperfusion injury pathology .....	109
1.2	Liver of <i>h-COX-2 Tg</i> mice have less tissue damage compared to the <i>Wt</i> animals .....	109
1.3	A mixed genetic background is required to reproduce the ischemia-reperfusion injury model in mice .....	112
1.4	Lower hepatic damage is due specifically to COX-2 expression .....	114
1.5	Hepatic preconditioning attenuates liver damage in <i>Wt</i> mice .....	115
1.6	The gene expression profile is altered after ischemia-reperfusion injury .....	117
2.	THE INFLAMMATORY RESPONSE IS ATTENUATED WHEN COX-2 IS EXPRESSED .....	119
2.1	Ischemia-reperfusion increases inflammatory markers that are lower in <i>h-COX-2 Tg</i> mice .....	119
2.2	Neutrophil infiltration is decreased with COX-2 expression .....	121
2.3	COX-2 expression attenuated NF- $\kappa$ B pathway .....	123
3.	CELLULAR STRESS IS REDUCED WHEN COX-2 IS EXPRESSED IN HEPATOCYTES .....	124
3.1	Constitutive hepatocyte COX-2 expression leads to decreased apoptosis .....	124
3.2	Hepatocyte COX-2 expression activates autophagy after ischemia-reperfusion .....	126
3.3	Unfolded protein response is activated in ischemia-reperfusion .....	127
3.4	The antioxidant response is enhanced when COX-2 is overexpressed .....	130
4.	STUDY OF THE MITOCHONDRIAL FUNCTION .....	134
4.1	Mitochondrial respiration is higher in <i>h-COX-2 Tg</i> livers after ischemia-reperfusion .....	134
4.2	Higher respiration in <i>h-COX-2 Tg</i> mitochondria is not due to an increase in ETC complexes expression .....	138
4.3	Ischemia-reperfusion causes lost in mitochondrial membrane potential and is prevented by COX-2 expression .....	140
4.4	Mitochondria number and phenotype are not altered because of the COX-2 expression .....	141
4.5	Mitochondrial dynamics is altered after ischemia-reperfusion .....	144
4.6	OPA1 processing is enhanced by a higher activity of OMA1 in <i>Wt</i> mitochondria after ischemia-reperfusion .....	146
5.	INCREASED PLASMATIC PGE <sub>2</sub> ARE ASSOCIATED WITH AN IMPROVEMENT IN LIVER FUNCTION .....	148

<b>V.</b>	<b>DISCUSSION.....</b>	<b>151</b>
<b>VI.</b>	<b>CONCLUSIONS .....</b>	<b>171</b>
<b>VII.</b>	<b>BIBLIOGRAPHY .....</b>	<b>175</b>
<b>VIII.</b>	<b>ANNEXES .....</b>	<b>203</b>
	ANNEX 1 – PATIENT INFORMATION TABLE .....	205
	ANNEX 2 – INDEX OF FIGURES .....	211
	ANNEX 3 – INDEX OF TABLES.....	215
	ANNEX 4 – PUBLICATIONS .....	217